SHARP trial

SHARP trial. The Study of Heart and Renal Protection was a landmark international randomized controlled trial investigating the effects of cholesterol-lowering therapy in patients with chronic kidney disease. Coordinated by the Clinical Trial Service Unit at the University of Oxford, it sought to determine whether reducing low-density lipoprotein cholesterol could decrease the incidence of major atherosclerotic events in this high-risk population. Its findings, published in the prestigious medical journal The Lancet, significantly influenced subsequent clinical guidelines for renal and cardiovascular care.

Background and Rationale

Prior to the initiation of this research, patients with advanced chronic kidney disease or those undergoing dialysis represented a population with exceptionally high rates of cardiovascular disease and mortality. Observational studies, such as those from the United States Renal Data System, consistently documented this elevated risk. However, evidence from earlier trials like the 4D trial in Germany and the AURORA trial, which focused on patients receiving hemodialysis, had failed to demonstrate a clear benefit from statin therapy alone on cardiovascular outcomes. This created clinical uncertainty, prompting investigators to design a broader study that included both pre-dialysis and dialysis-dependent patients, utilizing a combination of ezetimibe and simvastatin to achieve more substantial cholesterol reduction.

Study Design and Methods

The trial employed a multicenter, randomized, double-blind, placebo-controlled design, enrolling over 9,000 participants from more than 380 hospitals across Europe, North America, and Australasia. Eligible patients had a history of chronic kidney disease but no known prior myocardial infarction or coronary revascularization. Participants were randomly assigned to receive either a daily combination tablet containing ezetimibe and simvastatin or a matching placebo. The primary endpoint was a composite of major atherosclerotic events, defined as non-fatal myocardial infarction, death from coronary heart disease, non-hemorrhagic stroke, or any arterial revascularization procedure. Follow-up continued for a median of approximately five years, with oversight from an independent data monitoring committee.

Results

The study successfully achieved a significant mean reduction in low-density lipoprotein cholesterol of approximately 0.85 mmol/L in the active treatment group compared to the placebo group. Regarding the primary outcome, treatment with ezetimibe/simvastatin led to a statistically significant 17% proportional reduction in major atherosclerotic events. Analysis of the components of the primary endpoint showed consistent reductions. Importantly, the treatment effect appeared similar for participants who were not on dialysis and those who were, though the absolute benefit was greater in the former group. The regimen was generally well-tolerated, with no significant increase in incidents of rhabdomyolysis or hepatotoxicity compared to placebo.

Interpretation and Clinical Significance

The findings provided the first conclusive evidence that cholesterol-lowering therapy could safely reduce the risk of major atherosclerotic events in a wide range of patients with chronic kidney disease. This resolved a longstanding controversy in nephrology and cardiology, directly challenging the null results from the earlier 4D trial and AURORA trial by including a broader patient population and using a more potent lipid-lowering strategy. The results strongly supported the use of ezetimibe/simvastatin for primary prevention of cardiovascular disease in this vulnerable group, influencing updates to guidelines from bodies like the Kidney Disease: Improving Global Outcomes foundation and the American College of Cardiology.

Subsequent Research and Legacy

The trial's publication stimulated further investigation into the management of cardiovascular risk in renal patients. It helped shape the design of subsequent studies, such as those examining PCSK9 inhibitors in similar populations. The data also contributed to extensive meta-analyses conducted by the Cholesterol Treatment Trialists' Collaboration, reinforcing the broad benefits of lipid-lowering across different patient subgroups. Its legacy endures in modern clinical practice, where the combination of ezetimibe with a statin is a recognized therapeutic option for patients with chronic kidney disease, cementing the principle that effective cardiovascular protection remains a critical component of comprehensive renal care.

Category:Clinical trials Category:Cardiology Category:Nephrology